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Ionizing radiation abrogates the 
pro-tumorigenic capacity of cancer-
associated fibroblasts co-implanted 
in xenografts
Maria Tunset Grinde1,2,*, Jørg Vik2,*, Ketil André Camilio3, Inigo Martinez-Zubiaurre2 & 
Turid Hellevik2,4
Cancer-associated fibroblasts (CAFs) are abundantly present in solid tumors and affect tumorigenesis 
and therapeutic responses. In the context of clinical radiotherapy, the impact of irradiated CAFs to 
treatment outcomes is largely unexplored. Aiming at improving radiotherapy efficacy, we have here 
explored the effect of radiation on the inherent pro-tumorigenic capacity of CAFs in animals. Ionizing 
radiation was delivered to cultured CAFs as single-high or fractionated doses. Tumor development 
was compared in mice receiving A549 lung tumor cells admixed with irradiated or control CAFs. 
Biological mechanisms behind tumor growth regulation were investigated by quantitative histology 
and immunohistochemistry. Viability assessments confirmed that irradiated CAFs are fully functional 
prior to implantation. However, the enhanced tumorigenic effect observed in tumors co-implanted 
with control CAFs was abrogated in tumors established with irradiated CAFs. Experiments to ascertain 
fate of implanted fibroblasts showed that exogenously administered CAFs reside at the implantation 
site for few days, suggesting that tumor growth regulation from admixed CAFs take place during initial 
tumor formation. Our work demonstrate that irradiated CAFs lose their pro-tumorigenic potential 
in vivo, affecting angiogenesis and tumor engraftment. This finding propose a previously unknown 
advantageous effect induced by radiotherapy, adding to the direct cytotoxic effects on transformed 
epithelial cells.
Solid tumors are complex tissues, consisting of aberrantly growing malignant cells and a cocktail of 
non-transformed cells that altogether play fundamental roles in cancer sustainability and therapeutic 
responses1–3. Intriguingly, the tight dependency of cancer cells to the stroma in which they grow reveals appealing 
diagnostic and therapeutic opportunities4–6. Carcinoma-associated fibroblasts (CAFs) are a heterogeneous and 
multifunctional population of mesenchymal cells that function as key drivers of tumorigenesis7–11. The presence 
of CAFs in large numbers is generally associated with high-grade malignancy and poor prognosis12, but a pro-
tective role for CAFs is also suggested13. The direct or indirect involvement of tumor-infiltrating CAFs in therapy 
resistance has long been acknowledged, and recent reports have indicated that secreted factors produced by cells 
of the tumor microenvironment are interfering negatively with the response of cancer cells to chemotherapy 
and targeted drugs14,15. However, in the context of radiotherapy (RT), despite its extended use and impact in 
cancer management16, relatively little knowledge exists regarding the role played by non-malignant stromal cells 
in patient outcome post-RT17. Pre-clinical and clinical studies have suggested that tumor responses to ionizing 
radiation (IR) may be influenced by the microenvironment18–20, especially considering that in clinical settings, all 
tumor-associated host cells within the planning target volume will receive the same prescribed radiation dose as 
adjacent malignant cells. Hence, to improve cure rates from treatment strategies involving radiotherapy, and to 
avoid future relapses post-RT, it is vital to uncover the global cellular and molecular responses triggered by RT in 
all the tumor elements, including contributions effectuated by non-malignant cells20–22. Given the fundamental 
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role played by CAFs on general tumor growth regulations11,23, we hypothesized that CAFs may change their phe-
notype and pro-malignant nature upon irradiation, and that this circumstance could influence the ultimate fate 
of tumors post-radiotherapy.
In the past, we have studied the effects of ionizing radiation on primary CAF cultures directly isolated from 
lung tumor specimens. Despite displaying a prominent radio-resistant phenotype, exposure of primary human 
lung CAFs to single high-dose RT induces permanent DNA-damage responses and irreversible senescence, pro-
motes enhancement of integrin-mediated focal contacts24, and alter the release of certain cytokines and growth 
factors25. In the latter study, effects of CAF-conditioned media on tumor cell growth and migration was also 
explored, but no significant differences were observed. In a more recent study we have also shown that radiation 
exposure do not alter the immunosuppressive abilities of CAFs26. In this work, we aimed at expanding our knowl-
edge by studying the impact of admixed irradiated CAFs on the fate of tumors grown in xenografts. Results from 
this study suggest that CAFs lose their pro-tumorigenic capacity after radiation exposure. Such findings uncover 
a previously unknown beneficial effect elicited by radiotherapy besides the direct killing of malignant cells.
Results
CAFs survive single-high dose and fractionated radiation doses. Initial experiments were con-
ducted to ascertain if the radiation schemes used for the in vivo experiments were critically affecting viability or 
performance of CAFs. Experimental settings were identical to the ones used later on for the in vivo trials prior to 
implantation. These preliminary tests confirmed that viability of CAFs (from 3 different donors) was comparable 
to non-irradiated controls, when measured 24 hours post-irradiation by Trypan blue exclusion assay (Fig. 1A). 
Similarly, the large majority of living cells from both irradiated and non-irradiated cultures were able to adhere to 
plastic after cell detachment, demonstrating good performance of the irradiated cells in terms of cell adhesion and 
spreading prior to implantation (Fig. 1B). Phenotypically, both control and irradiated CAF cultures showed abun-
dant and homogenous expression of the fibroblast marker platelet-derived growth factor-receptor-α (PDGFRα ) 
(Fig. 1C,D). The human specific antibody against PDGFRα was used in subsequent animal experiments to trace 
implanted CAFs.
Radiation abrogates the enhanced tumor-growth effects exerted by admixed CAFs. A funda-
mental part of this study was to determine if CAFs - upon exposure to ionizing radiation - maintain their well 
described tumor promoting effects when co-implanted with tumor cells. A series of pilot experiments in animals 
were therefore conducted to decide on the most optimal parameters for experimentation, such as most suitable 
tumor cell line, most suitable number of inoculated cells, rate of tumor growth with and without CAFs and 
best implantation strategy (monolateral vs. bilateral) (Fig. 1E–G). Chosen parameters for the main experiment 
are described in the methods section. Under such conditions, A549 lung cancer cells (1 × 106) injected either 
alone or admixed with non-irradiated or irradiated CAFs (1 × 106) were able to establish subcutaneous tumors 
in the flank of athymic mice. In the first large experiment (Fig. 2), four experimental groups were included (8 
mice/group), comprising 1) A549 lung tumor cells alone, 2) A549 admixed with non-irradiated CAFs, 3) A549 
admixed with single-high dose irradiated CAFs (1 × 18 Gy) and 4) A549 admixed with fractionated-irradiated 
CAFs (3 × 6 Gy). Five to ten days after implantation, palpable tumors were observed in the majority of the ani-
mals (Fig. 2A). Tumor growth curves representing two months of incubation are shown in Fig. 2B. Tumors were 
first observed in mice that received A549 tumor cells admixed with non-irradiated CAFs (group 2), indicating 
both improved tumor take (to 100%) and accelerated tumor growth in this group compared to the other groups 
(Fig. 2A,B). Additionally, A549 tumor cells co-implanted with control CAFs established tumors earlier, more 
frequently and with enhanced tumor growth kinetics (2–3 fold enhancement, p < 0.05) compared to tumors 
established exclusively with A549 tumor cells. Interestingly, tumor growth was slower in animals implanted with 
A549 and irradiated CAFs (groups 3 and 4), compared to tumor growth in animals receiving a mix of A549 
cells and non-irradiated CAFs (group 2) (p < 0.05) (Fig. 2B). Another radiation-induced effect observed in the 
group with co-implantation of fractionated-irradiated CAFs (A549 + f-iCAFs; 3 × 6 Gy) was reduced tumor-take 
(62.5%) compared to the control group (only A549)(87.5%) (Fig. 2A). Nevertheless, growth kinetics for these two 
groups were comparable (Fig. 2B).
Tumors were collected at endpoint (day 61), or when tumor diameters reached 10 mm. Some animals were 
sacrificed before the experimental endpoint due to necrosis/ulceration of tumor lesions. Hence, tumor volumes 
measured at day 41 post-implantation were largest in mice receiving A549 together with non-irradiated CAFs, 
whereas tumor-sizes in groups 3 and 4, containing irradiated CAFs, were comparable to tumors established with 
only A549 (Fig. 2C). Of note, metastatic lesions in lung or bone were not observed in any mice.
Mechanisms behind iCAF-mediated tumor growth regulation revealed by histopathology. 
Aiming at defining potential mechanisms behind the CAF-mediated tumor growth regulations, we performed 
quantitative histology and immunohistochemistry analyses of major tumor biological markers, including prolif-
eration rate, extent of necrosis, angiogenesis, matrix deposition, and tumor infiltration by inflammatory cells and 
fibroblasts. Software-based quantitative determinations of Ki-67 (proliferation), hematoxyline and eosin (H&E) 
(necrosis), and Masson’s trichrome (MT) (connective tissue/collagen) revealed no significant differences between 
experimental groups (Fig. 3). Ki-67 staining demonstrated that (20–35)% of tumor cells were in a proliferating 
phase, whereas Masson’s trichrome staining of collagen revealed that connective tissue in tumors represented 
(0–10)% of total tumor area. H&E-staining visualized large variability in extent of tumor necrosis, ranging from 
0% to near 100% of total tumor area. Of note, large variability in necrosis and collagen deposition in tumors 
within the same experimental groups was observed.
Intriguingly, quantification of microvessel-density by the endothelial cell marker CD31 revealed that tum-
ors grown in the presence of irradiated CAFs had enhanced micro-vessel formation, relative to tumors grown 
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Figure 1. Viability of irradiated CAFs & Tumor growth characteristics. Viability (A) and plating efficiency 
(B) of cultured irradiated CAFs, prior to implantation. In (A), viability was measured 24 hours after last 
radiation dose. In (B), plating efficiency of CAFs also 24 hours post-IR. Columns in A and B show values from 
one CAF donor and are representative outcomes from three different donors. In (C,D) fluorescent micrographs 
of cultured human lung CAFs stained with anti-human PDGFRα antibody (red) and nuclear DNA (DAPI, 
blue). Panel (D) shows PDGFRα -staining of CAFs that were irradiated (1 × 18 Gy) and fixed 5 days post-IR. 
Panels (E–G) demonstrate tumor growth curves for xenografts established s.c. in athymic nude mice in pilot 
experiments. In (E), tumor take and growth from two different human lung tumor cell lines, A549 and H520, 
was compared. In (F), tumor growth characteristics of bilateral tumors established with tumor cells vs. tumor 
cells/CAFs. Left flank was inoculated with only A549 cells (1 × 106), whereas right flank received a mix of 
A549 cells (1 × 106) and CAFs (1 × 106). In (G), comparative tumor growth kinetics in animals inoculated with 
admixed control CAFs or irradiated (1 × 18 Gy) CAFs. CAFs were irradiated 24 hours prior to implantation. 
Tumor area: A = π·l·b.
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without CAFs (p = 0.009) or with non-irradiated CAFs (p = 0.029) (Fig. 3, bottom panels). Additionally, tumors 
established with fractionated-irradiated CAFs (3 × 6 Gy) demonstrated higher microvessel density than CAFs 
exposed to a single-high dose of radiation, albeit the differences were not statistically significant between these 
groups. Staining of tumors with the murine fibroblast marker27 fibroblast activation protein-1 (FAP-1) revealed 
substantial infiltration of host fibroblasts in most tumors. Although significant differences were not observed 
between experimental groups, we identified a trend towards increased numbers of FAP-1+ cells (i.e. host fibro-
blasts) in tumors established with irradiated CAFs (1 × 18 Gy) relative to tumors established with only cancer 
cells.
The extent of inflammatory reactions and immune cell infiltration was studied by the use of specific mark-
ers that identify inflammatory/immune cells, including inducible nitric oxide synthase (iNOS) to detect type-I 
(M1) macrophages, arginase-1 (Arg1) to detect type-II (M2) macrophages and myeloperoxidase (MPO) to detect 
neutrophils. To increase the accuracy in evaluating these markers, we divided the scorings into peritumoral and 
intratumoral marker expression (Fig. 4). Tumors from all experimental groups were to some extent infiltrated by 
murine immune cells, including macrophages and neutrophils, as shown in Fig. 4. However, most of the late-stage 
tumors revealed low levels of intratumoral M2-macrophages (Arg1+; (0–5)%) and M1-macrophages (iNOS+; 
Figure 2. Tumor take & Tumor growth kinetics in xenografts. Monolateral xenograft tumors were established 
s.c. in athymic Balb/c nu-nu mice. (A) Timeline reflecting tumor take and growth kinetics between 
experimental groups. Green  indicates time-points when tumors reached 4 mm; Red  reflects time-points 
when tumors reached 7 mm; Black X: reflects tumors retrieved due to ulceration or with diameters ≥ 10 mm. (B) 
Tumor growth kinetics: (○ ) A549 lung tumor cells (n = 7), (◊ ) A549 tumor cells with control CAFs (n = 8), (● ) 
A549 tumor cells with irradiated CAFs (iCAFs) (1 × 18 Gy) (n = 7), (▪ ) A549 tumor cells with fractionated-
irradiated CAFs (3 × 6 Gy) (n = 5). (C) Tumor volumes at 41 days post-implantation. Group 1 (n = 7); group 2 
(n = 8); group 3 (n = 7); group 4 (n = 5). Differences in tumor volumes between group 1 and 2 were statistically 
significant (*p < 0.05), and borderline significant between group 2 and groups 3 or 4 (p = 0.061 and 0.067, 
respectively).
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Figure 3. Quantitative assessments of tumor biological markers by histopathology. Tissue sections from 
tumor xenografts harvested 41–61 days post-implantation were stained for Ki-67 (proliferation), Masson’s 
trichrome/MT (collagen ), H&E (necrosis), FAP-1 (human/murine CAFs), and CD31 (endothelial cells). Left 
panels; software-based quantitative evaluation of staining. Each dot represent the average value of multiple 
images taken from same tumor (one dot/animal). Right panels show representative images of the different 
markers taken from randomly selected tumors.
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(0–1)%). Peritumoral presence of macrophages (M1 and M2) had a wide range of values, reaching > 50% in some 
tumors, but most tumors had a lower score (< 5%). For neutrophils, all, except three tumors, were completely neg-
ative for MPO (infiltration < 5% of tumor area). Once again, substantial variations in scoring rates for immune 
markers were observed within each experimental group. Finally, the presence of implanted CAFs in tumors was 
checked by human-specific anti-PDGFRα antibody. Importantly, we could not identify implanted CAFs (or CAF 
remnants) in tumors in any of the experimental groups.
Fate of implanted fibroblasts in xenografts. The latter observation prompted us to explore the fate of 
transplanted CAFs in our model, and to elucidate if non-irradiated CAFs, in contrast to irradiated CAFs, undergo 
cell expansion in vivo. We conceived a double approach to answer this question, based on a) permanent intracel-
lular fluorescence labelling of cultured CAFs by the fluorochrome 5-chloromethylfluorescein diacetat (CMFDA); 
and b) detection of human CAFs in tumor tissue by a human-specific anti-PDGFRα antibody (Fig. 5A). Tumors 
were collected at various time-points post-implantation, including 1 week (earliest macroscopic manifestation 
of tumors), 2 weeks and 4 weeks (tumor diameters ~5 mm). Results from this experiment confirmed that in 
our tumor model, transplanted human CAFs were present at early stages after implantation (first week), but 
were not traceable in specimens collected 2 and 4 weeks after implantation. In some tumors, labelled cells had 
a spindle-shaped or fibroblast-like morphology (within healthy tumor areas) while in other tumors the labelled 
cells displayed a more round morphology (normally associated to tumors with extended necrosis). Likewise, 
the presence of irradiated CAFs was also checked in tumors collected at early time-points post-implantation 
(Fig. 5B). We confirmed that irradiated CAFs were indeed present at the implantation site during the first week 
after inoculation of cells. The final fate of transplanted CAFs is uncertain, but based on the frequently observed 
apoptotic-like round morphology of labelled cells, and the presence of abundant subcellular remnants, we spec-
ulate that most implanted CAFs might gradually die in situ some few days after implantation. To validate the 
successful transplantation of irradiated CAFs, we quantified human CAFs based on PDGFRα expression in 
one-week-old tumors (Fig. 5C). Results from these measurements show that CAF transplantation was successful 
Figure 4. Assessments of inflammatory cell infiltration in tumors harvested at late stages. Tissue sections 
from tumor xenografts harvested at end-point of study, i.e. 41–61 days post-implantation of cells, were immune-
labelled for iNOS (M1-macrophages), Arg1 (M2-macrophages) or MPO (neutrophils). Intratumoral and 
peritumoral scores in left and right panels, respectively. Middle panel; representative images from each staining 
from randomly selected tumors.
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Figure 5. Fate of human CAFs co-transplanted in A549 xenografts. (A) Time-course experiment showing 
presence/absence of implanted human CAFs in tumors harvested at 1, 2 and 4 weeks post-implantation.  
(B) Detection of irradiated CAFs (1 × 18 Gy) in tumors 1 week post-implantation; Exogenously administered 
CAFs are visualized by green CMFDA fluorescence (left panels) and by immune-staining against human-
specific anti-PDGFRα antibody (right panels). (C) Blinded quantitative scorings of PDGFRα -positive 
fibroblasts in early tumor tissues with admixed CAFs.
www.nature.com/scientificreports/
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in all experimental groups. The relative lower numbers of human CAFs in the group of tumors established with 
CAFs exposed to a single-high (1 × 18 Gy) dose of radiation could be explained by radiation-induced senes-
cence24 and the consequent loss of cell division in comparison to the two other groups. Of note, the control group 
and the fractionated-irradiated (3 × 6 Gy)-group demonstrated comparable numbers of transplanted CAFs.
Tumor biological features examined by histopathology at early stages of tumor growth. Since 
admixed CAFs (both irradiated and non-irradiated) were only present at early stages of tumor formation, we 
decided to check again for relevant tumor biological features in tumors collected immediately after becoming 
macroscopically detectable (7–10 days post-implantation). Thus, a similar main experiment as the one car-
ried out initially was performed, with the only exception that tumors were collected shortly after implantation. 
Twenty-five small tumors (of 32 inoculated animals) could be collected when tumors became palpable. The same 
list of tissue markers used in the previous experiment were examined in early-stage tumors. In Fig. 6 (tumor 
biological markers) and Fig. 7 (immune/inflammatory cells), dot plots with means for each group are presented. 
In general, the new analyses in early-formed tumors revealed comparable results as in late-stage tumors, showing 
analogous differences between groups for basically all the tested markers. Unfortunately, the variance of values 
within groups kept being quite high also in early-collected tumors. Regarding microvessel density, a similar trend 
as in late-stage tumors was found; marked by increased values in tumors from the fourth group (A549 + iCAFs; 
3 × 6 Gy) (Fig. 6). The results were however not significant (p = 0.075). Of note, IHC staining demonstrated that 
xenografts at early time-points were extensively infiltrated by host immune cells, including macrophages and 
neutrophils, as shown in Fig. 7. However, intratumoral and peritumoral infiltration was highly variable within 
groups for all tested immune markers. Importantly, by comparing histopathological scores between early- and 
late-stage tumors, some clear differences were observed. For instance, the number of vessels per area (detected 
by CD31-stains) was about (5–10)-fold elevated in early stage versus late stage tumors (Figs 3 and 6, bottom 
panels). Moreover, macrophages and neutrophils were more abundantly present in early stage compared to late 
stage tumors.
Discussion
In the context of clinical radiotherapy, both cancerous cells and the rest of tumor-associated host cells receive 
the same prescribed radiation dose. Under injurious circumstances such as those instigated by radiotherapy, 
fibroblasts are probably one of the most resistant cell types and could therefore participate towards tumor relapse. 
Hence, the aim of this study was to evaluate the potential tumor growth regulatory effects exerted by irradiated 
CAFs in vivo. The experimental strategy comprised subcutaneous implantation of tumor cells admixed with 
irradiated or non-irradiated CAFs in athymic mice. Here we demonstrate that, at least in this xenograft model, 
CAFs lose their natural pro-tumorigenic properties upon exposure to ionizing radiation. This outcome represents 
a gainful effect exerted by radiotherapy that has not been described hitherto.
To unveil the contribution of CAFs in tumor development and therapeutic outcomes, researchers have relied 
on preclinical tumor models that include co-implantation of different cell types. In our model, admixed CAFs 
clearly enhance engraftment and tumor growth compared to engraftment with tumor cells only. Several studies 
have demonstrated that co-injection of Matrigel28 or normal fibroblasts along with tumor cells29–33 is able to 
bypass the tedious process of stromal cell recruitment and activation34, resulting in improved tumor take and 
accelerated tumor formation32. However, in some animal models of breast35,36 and prostate cancers37, it has been 
demonstrated that admixed CAFs constitute a rate-limiting factor for tumor progression23, exerting even more 
powerful tumor enhancing effects than normal fibroblasts or Matrigel32. The latter fact highlights the importance 
of the phenotypic differences between quiescent/normal and activated fibroblasts10,31,35,38.
Among the possible mechanisms behind CAF-mediated tumor growth regulation in vivo, it has been fre-
quently observed an enhancement of angiogenesis during early phases of tumor formation via secretion of mis-
cellaneous CAF-derived factors, including SDF-1/CXCL1235, CXCL1439, FGF-240,41, PDGF42, IGF243, TGFβ 44,45 
or CTGF46. Alternative suggested mechanisms are increased deposition of basement membrane components 
in tumors30, expression of fibroblast activation protein (FAP-1)47, metalloproteinase 2 (MMP-2)48 or cofilin-1 
and IL-649. In addition, CAFs are able to directly modulate the recruitment, polarization and function of innate 
immune cells via secretion of cytokines and chemokines such as CCL2, CXCL1 or CXCL1450. In this study, we 
have analyzed angiogenesis, inflammation and other major tumor biological features by histology and immu-
nohistochemistry. In tumors retrieved at late stages of growth we have not observed significant differences in 
the extent of angiogenesis between tumors formed by only tumor cells or admixed with control CAFs. Other 
essential parameters such as desmoplastic reactions, tumor cell proliferation or inflammatory cell infiltration also 
remained comparable between experimental groups. Nevertheless, it is important to consider that the intragroup 
variability found for most markers in our model was considerably high and could have influenced the statistical 
significance of the results.
The lack of significantly relevant CAF-mediated effects on tumor biological parameters at late stages of growth 
prompted us to explore the fate of CAFs following implantation. Indeed, certain controversy exists on to which 
extent implanted human CAFs persist at the injection site during tumor development. Some authors claim that 
CAFs have left the injection site already 13 days after being co-implanted41, whereas others have reported that 
CAFs are found in tumors even 30 days post-injection35. Nonetheless, the majority of laboratories that have 
studied this particular aspect coincide on the view that regardless of tumor model or implantation site used, 
exogenous fibroblasts only reside at the injection site during early stages of tumor formation41,48,51–53. Our model 
faithfully reproduce the same scenario observed by many others, where human CAFs become untraceable already 
2 weeks post-implantation, and tumors become instead infiltrated by host fibroblasts. This observation allows 
thinking that implanted human CAFs exert their effects at very early stages of tumor formation, apparently affect-
ing aspects related to tumor cell engraftment, early tumor cell survival, early angiogenesis or early inflammatory 
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Figure 6. Tumor biological markers in early-stage xenografts. Tissue sections from tumor xenografts 
harvested 7–10 days post-implantation were stained for Ki-67 (proliferation), Massons trichrome/MT (collagen 
deposition), H&E (necrosis), FAP-1 (human/murine CAFs), and CD31 (endothelial cells). Left panels show 
quantitative determinations of markers, one dot per animal. Right panels show representative images of the 
different markers taken from randomly selected donors.
www.nature.com/scientificreports/
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reactions. Because of the last mentioned observation, we repeated the experiments, but collected tumors early, 
i.e. when neoplasms were barely visible (7–10 days post-implantation). In line with what was expected, levels of 
neo-angiogenesis and rate of inflammatory cell infiltration was higher in early than late collected tumors, coin-
ciding with onset of local inflammatory reaction after cell transplantation. However, we did not find statistically 
significant differences in tumor biological features that could explain increased tumor cell engraftment in animals 
receiving tumor cells and control (non-irradiated) CAFs.
The most relevant finding in our study is the observation that CAFs lose their pro-tumorigenic effects after 
exposure to ionizing radiation, given as a single-high dose (1 × 18 Gy) or oligo-fractionated doses (3 × 6 Gy). We 
will emphasize that the irradiated CAFs used in this study were alive and functional at the time of implantation. 
In fact, other scholars in the field have previously demonstrated that the fibroblast is a highly radioresistant cell 
type, and that fibroblasts established in culture dishes may survive single doses above 30 Gy54–56. The effect of ion-
izing radiation on fibroblasts, both on normal and cancer-associated fibroblasts, has been studied to some extent 
in vitro. Of interest, simultaneous irradiation of normal fibroblasts and murine (adenocarcinoma) lung tumor 
cells in co-culture reportedly was abrogating the pro-migratory phenotype of these carcinoma cells57. Others have 
performed transcriptome studies, comparing irradiated and non-irradiated fibroblasts, and have thus revealed 
profound changes in biological functions and processes involved in DNA repair, activation of stress responses, 
cell cycle arrest, senescence-associated genes, autophagy regulatory elements, ROS production and immune 
responses54,58,59. Our group has previously shown that irradiated lung-CAFs become prematurely senescent (80% 
rate by 1 × 18 Gy, 50% rate by 6 × 3 Gy), slow down their proliferative rate, and display reduced migratory func-
tion24. Most importantly, the pattern of CAF-secreted proteins comprising numerous inflammatory mediators, 
extracellular matrix proteins, proteases, growth factors, chemokines and cytokines become significantly altered 
after irradiation24,25. Studies on CAF responses to IR have unveiled intriguing changes in the secretion of parac-
rine signal molecules, including enhancement of bFGF and reduction of CTGF and SDF-125. In this study, we do 
not see clear changes in the patterns of ECM deposition, host fibroblast recruitment or tumor cell proliferation. 
However, we do observe enhanced neo-angiogenesis in tumors formed with admixed fractionated-irradiated 
CAFs, both at early (1.7-fold) and late (3.3-fold) tumor formation. This observation is in agreement with 
Figure 7. Immune-specific markers in early tumors. Histology of tumor xenografts harvested at early stages 
of tumor growth (7–10 days post-implantation). Tumor tissue sections were labelled with antibodies against 
iNOS (M1-macrophages), Arg-1 (M2-macrophages) and MPO (neutrophils). Intratumoral and peritumoral 
scores shown in left and right panels, respectively. Middle panel shows representative images of the different 
markers taken from randomly selected donors.
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1 1Scientific RepoRts | 7:46714 | DOI: 10.1038/srep46714
previous analyses of the iCAF secretome, demonstrating increased release of bFGF and decreased release of 
the anti-angiogenic factors thrombospondin-1 and -2 after radiation exposure25. Interestingly, the presence of 
implanted CAFs, and in particular fractionated-irradiated CAFs, triggered enhanced infiltration of macrophages 
and neutrophils in early tumors. Microvessel density – both at early and late tumor formation - displayed a sim-
ilar trend, with maximal vessel density in tumors initiated with fractionated-irradiated CAFs. Nevertheless, the 
enhanced angiogenesis in the irradiated-CAF groups may be interpret as a controversial finding, since the tumor 
volume of xenografts initiated with admixed irradiated CAFs is actually reduced. We speculate that in our mouse 
model, the process of vessel formation and development of functional vasculature in tumors is inefficient and 
therefore, early enhancement of endothelial cell infiltration does not support eventually enhanced tumor growth. 
In fact, vessel density parameters were considerably lower in tumors collected at late compared to early stages of 
growth.
The available literature on tumor growth regulations by irradiated fibroblasts in vivo is scarce. In this con-
text, it is utterly important to consider that most available data comes from models that comprise normal tis-
sue fibroblasts or immortalized fibroblast cell lines instead of primary cultures of reactive10,60 tumor-associated 
fibroblasts51,56,61. Some of the referred studies do not focus on radiation effects per se, but rather aim at exploring 
cellular senescence, using radiation as an experimental tool for senescence induction56,62. With this background 
in mind, other laboratories have demonstrated that at radiation doses exciding 1 × 10 Gy, the phenotype of fibro-
blasts become altered, with induction of irreversible DNA-damage responses and development of stress-induced 
senescence24,62. In the cancer setting, senescent fibroblasts play deleterious roles by contributing to chronic 
inflammatory reactions, promoting angiogenesis and nourishing growth and invasion of transformed epithelial 
cells56,62. In our study, we observe opposite effects. The irradiated lung CAFs we have used here turn senescent 
several days after IR exposure24, however, they lose their tumor-supporting characteristics, with a demonstrated 
prolonged latency, reduced tumor-take and retarded tumor growth. Our tissue examinations were insufficient 
to explain the mechanisms behind the observed effects. Of note, in tumors collected at early stages, we observed 
a reduced number of implanted CAFs in the experimental group receiving admixed CAFs pre-treated with a 
single-high radiation dose (1 × 18 Gy) (Fig. 5). We cannot exclude the option that an accelerated cellular decay 
of CAFs receiving such high radiation dose could be the reason behind the reduction in tumor promotion. In 
such case, CAF-derived effects would not be attributable to radiation-induced phenotypic changes, but plainly to 
increased cell death. On the contrary, we observe comparable numbers of transplanted CAFs when comparing the 
non-irradiated group and the (3 × 6 Gy)-irradiated group, the latter group clearly showing a significant reduction 
in tumor promotion. In this case, the loss of tumor enhancing effects is likely attributable to radiation-induced 
phenotypic changes in CAFs. Importantly, other authors have also questioned the tumor-enhancing nature of 
irradiated or senescent fibroblasts33,57,61,63.
In conclusion, in this study we unveil a new advantageous effect elicited by radiotherapy, which adds to the 
direct killing of transformed epithelial cells, in the form of silencing the natural tumor-promoting actions of 
CAFs. Analyses of crucial tumor biological features by histopathology, combined with earlier knowledge about 
radiation-mediated effects on CAFs were not sufficient to address the mechanisms behind the observed tumor 
growth regulation. Further studies using perhaps other tumor cell lines and more sophisticated animal models 
- such as orthotopic or patient-derived xenografts or genetically engineered mouse models - will be needed to 
make measurable improvements in our understanding on the contribution of CAFs to radiotherapy outcomes.
Materials and Methods
Lung cancer cell lines. Human lung cancer cell lines A549 (lung adenocarcinoma) and NCl-H520 (squa-
mous cell carcinoma) were purchased from LGC Standards AB (Borås, Sweden). Cells were cultivated in a 
humidified incubator at 37 °C, containing 5% CO2 and 20% O2. Incubation medium consisted of RPMI-1640 
supplemented with 10% heat deactivated fetal bovine serum (FBS), L-glutamine and penicillin (1%) and strep-
tomycin (1%).
Human material, CAF isolation and cultures. Human lung CAFs were isolated from freshly resected 
non-small cell lung carcinoma (NSCLC) tumor tissue from patients undergoing surgery at the University 
Hospital of Northern Norway, Tromsø. Lung tumor specimens from four different donors were included in the 
study. The Regional Committee for Medical and Health Research Ethics (REK-Nord) approved the use of human 
material for this study (Project-ID: 2009/895-4), and informed written consent was obtained from all patients. 
All methods involving human material were performed in accordance with relevant guidelines and regulations. 
Upon surgical resection of tumors, fibroblasts were isolated by the outgrowth method, as previously described24. 
Mesenchymal-like cells were selected by differential cell detachment, and further expanded in serum-containing 
incubation medium. CAFs were characterized for the presence of lineage specific markers at the third passage, 
using flow cytometry and immunocytochemistry24. Isolated CAFs were used for experimentation after third and 
fourth passage (3–4 weeks-old cultures).
Irradiation of cells. Adherent CAF cultures prepared in T-75 flasks were irradiated when 70–90% confluent 
with high-energy photons, using a clinical Varian linear accelerator, as previously described24. Ionizing radiation 
was delivered to cell cultures either as a single-high dose (1 × 18 Gy) or as fractionated exposures (3 × 6 Gy) in 
24 h intervals. Standard parameters for dose delivery was depth 30 mm, beam quality 15 MV, dose rate of 6 Gy/
min and field sizes of 20 × 20 cm. The (last) dose of radiation was given 24 hours before injection of cells into mice. 
Thermo-Luminescent Dosimeters (TLDs) were applied to confirm dose-delivery within an acceptable ± 4%.
Viability and plating efficiency assays. CAFs from the same donors as those used in the animal experi-
ments were irradiated in the same way as cells utilized for in vivo studies, and 24 hours post-irradiation examined 
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for viability and adherence capacities. For that purpose, twenty-four hours after the last radiation exposure, cells 
were incubated with Enzyme-Free Cell Dissociation Solution (Merck Millipore), then detached and spun down 
(400 g, 3 min). Resulting cell pellets were dissolved in 500 μ L cold medium and kept on ice for 45 min to mimic 
the procedure for cell implantation. Cell viability was determined by Trypan blue exclusion assay, and percentage 
viable cells was estimated by dividing number of cells without dye against total number of cells. For analysis of 
plating efficiency, the harvested cells were transferred to a T-25 flask and incubated further (24 hours, 37 °C) for 
cell adherence. After incubation, non-adherent cells was counted, and plating efficiency (%) was calculated in 
relation to total sum of adherent and non-adherent cells.
In vivo xenograft model. Female nude athymic mice (NU/NU Nude Mouse Crl:Nu-Foxn1nu, age 6-7 
weeks), weighing 23.3 ± 2.0 g were purchased from Charles River (Sulzfeld, Germany), and acclimatized in the 
local animal facility for minimum five days before experimentation. All procedures and experiments involving 
animals were conducted according to regulations by the Federation of European Laboratory Animal Science 
Association (FELASA) and was approved by the National Animal Research Authority (permission ID 6373, 6942 
and 7873). All cells used for implantation were tested for pathogens by Charles River Laboratories International 
Inc. (Human Comprehensive test, Charles River). Pilot trials were conducted to ascertain the most suitable lung 
tumor cell line for xenograft formation (between A549 and H520) and optimal amount of implanted cells to 
achieve stable tumors. For the main experiment, mice received tumor cells alone (A549, 1 × 106 cells/mouse), or 
tumor cells admixed with (Sham)-irradiated CAFs (1 × 106 cells/mouse). In the second large experiment, for 
checking tumor features at early stages, we used a tumor cells/CAFs ratio of 2:1 in order to increase the rate of 
tumor take in animals from the irradiated groups. Cells utilized for implantation were prepared in culture 
medium (RPMI + 10% FBS) and injected s.c. into the right flank of animals (50 μ L/mouse). Tumors were meas-
ured twice per week using a digital caliper, and tumor volumes were calculated ( = ⋅ ⋅π l w dV ( )
6
). In the exper-
iment dedicated to tumor growth kinetics analyses, animals were sacrificed when tumors reached diameters of 
10–12 mm or, eventually, at the experimental endpoint (day 61). Some animals were euthanized before endpoint 
of experiment due to animal welfare (necrotic tissue in tumor (N = 7), necrotic tail (N = 1), other reasons (N = 1). 
In the second experiment, which focused on early tumor formation, tumor tissues were harvested when tumors 
became macroscopically visible and palpable.
Histopathology and immunohistochemistry (IHC). Medium and small-sized tumors were 
directly immersed into ice-cold 4% paraformaldehyde (PFA) in PBS upon excision, whereas large tum-
ors were perfusion-fixated in situ with 4% PFA, excised and stored (24–48) h at 4 °C in 2% PFA/PBS before 
paraffin-embedding. Tumor tissues were thereafter cut into thin sections (5 μ m) with a cryostat, and sections 
deparaffinized and rehydrated prior to antibody labelling. Necrotic areas were identified in slides stained with 
hematoxyline and eosin, whereas interstitial collagen depositions were visualized by Masson’s trichrome staining. 
Cellular proliferation (Ki-67), microvessel density (CD31) and immune cells infiltration were identified by immu-
nostaining. Antibodies utilized for immunohistochemistry analyses are presented in Table 1. Antigen retrieval 
was mediated by heating sections in citrate buffer (10 min, 95 °C). IHC staining was executed by applying a rabbit 
specific HRP/DAB detection kit (Abcam, ab64261, UK). For the specific detection of Ki-67, secondary stain-
ing was carried out using the UltraView Universal DAB Detection Kit (Roche, 760–500), and performed on a 
BenchMark XT or BenchMark Ultra platform (Ventana Medical Systems, Arizona, US).
Image acquisition and quantitative analyses. Image analysis was performed in a blinded manner, by 
masking the identity of sections prior to image acquisition. Multiple images per tumor specimen (1 to 8, depend-
ing on tumor size) were acquired with a Leica CTR6000 microscope (Leica Microsystems, Germany) equipped 
with a Leica DFC320 digital color camera. Images were collected in a predetermined systematic pattern, with 
a random starting point. Tissue sections stained for FAP1 and Ki-67 were imaged at 400X, whereas sections 
stained with H&E and Masson´s trichrome as well as CD31, iNOS, Arg-1 and MPO antibody-labelled sections 
were imaged at 100X. Quantitative scores per mouse represent average values based on all images collected from 
a single tumor. The plugin Immunoratio for ImageJ was used for computer-assisted analysis of Ki-67 staining, 
according to Tuominen et al.64 Collagen quantity in images from Masson´s trichrome staining was determined 
by HSI-thresholding in NIS Elements AR 3.10 (Nikon Instruments), and the same program was also applied to 
quantify the extent of necrosis in H&E-stained slides, and for determining CD31+-microvessels, essentially as 
Marker Antibody Species reactivity Supplier and catalogue no. Host species Antibody dilution
Proliferation Anti-Ki67 Human Roche 790-4286 Rabbit Prediluted
Endothelial cells/angiogenesis Anti-CD31 Mouse, human, pig Abcam Ab28364 Rabbit 1:75
Neutrophiles granulocytes Anti-MPO Mouse, human, rat Life Technologies PA5-16672 Rabbit 1:100
M1-macrophages Anti-iNOS Mouse and rat Abcam Ab15323 Rabbit 1:100
M2-macrophages Anti-Arginase1 Mouse, rat, human Santa Cruz Biotechnology, Sc-20150 Rabbit 1:200
Host fibroblasts Anti-Fap1 Mouse, rat and human Abcam Ab53066 Rabbit 1:100
Human CAFs Anti-PDGFRα Human Cell Signaling D13C6 Rabbit 1:50
Table 1.  Overview of primary antibodies, their species reactivity, suppliers and product information, host 
species, and antibody dilution used during immunohistochemistry staining.
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described in ref. 65. Images were collected in a random systematic pattern, due to lack of hot spots in many of 
our tumors.
In images representing FAP-1 and MPO stained sections, a semi-quantitative cell density scoring system was 
devised: a) FAP-1: 0 = (0–1 positive cells)/field; 1 = (2–10 positive cells)/field; 2 = (11–25 positive cells)/field; 
and 3 = (> 25 positive cells)/field; b) MPO: 0 = (0–5)% positive staining/tumor area; 1 = (5–25)%; 2 = (26–50)%; 
3 = (> 50%). Scoring-system for intratumoral infiltration of Arg-1+ cells was (0 = (0–5)% positive staining/tumor 
area; 1 = (5–25)%; 2 = (26–50)%; 3 = (> 50%) and for iNOS (0 = (0–1)%; 1 = (2–5)%; 2 = (6–15)%, 3 = (> 16)), 
whereas peritumoral infiltration for the latter two markers was scored as: 0 = (0–5)%; 1 = (5–25)%; 2 = (26–50)%; 
3 = (> 50%). Results represent average from two researchers scoring independently. Discordance in results bigger 
than one were solved with a discussion and rescoring.
CAF fate and CMFDA staining. To track implanted human CAFs in tumors, we identified CAFs in 
resected tumor tissues by two independent labelling methods. Firstly, CAFs in monolayers were fluorescence 
labelled, based on intracellular accumulation of cell tracker Green CMFDA (5-chloromethylfluorescein diac-
etate, Molecular Probes). To this end, CAFs were allowed to internalize CMFDA (5 μ M) for 30 min, accord-
ing to the manufacturer’s instruction, and 24 hours before implantation. CMFDA-labelled CAFs (1 × 106), 
were co-implanted with A549 cells (1 × 106) and injected (s.c.) into mice. Xenograft tumors established in 
animals were collected at one, two and four weeks after implantation. Excised tumors were fixed in 4% PFA 
(4 °C), paraffin-embedded and sectioned with a cryostat. Sections were directly examined for the presence 
of CMFDA-containing CAFs in a fluorescence microscope. Alternatively, tumor sections were stained with 
human-specific anti-PDGFRα antibody for detection of implanted human CAFs. For quantitative determi-
nations, PDGFRα +-cells were counted in (2–3) random, non-overlapping areas of tumors. Semi-quantitative 
scorings were performed on PDGFRα -stained tumors according to the following indications: (0 = no staining; 
1 = weak staining; 2 = moderate; 3 = abundant). Scores per mouse represent average value for all inspected areas 
of one tumor.
Statistical analysis. One-way ANOVA followed by least significant difference (LSD) for post hoc analysis 
was used for multiple comparison when data were normally distributed. Kruskal-Wallis test followed by LSD post 
hoc analysis was used when data failed normality test. Normality of the data was investigated by visual inspection 
of QQ plots. All statistical testing was performed using SPSS (version 23). Significance was set at p < 0.05.
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